Nicox Provides Third Quarter 2022 Financial and Business Highlights
yahoo.com
news
2022-10-19 05:30:00

Topline results of the NCX 470 Mont Blanc Phase 3 glaucoma trial due i n early November 2022

Third quarter 2022 U.S. presc riptions for VYZULTA ® increased by 37 % over third quarter 2021

Net revenue €0.8 million for third quarter 2022; cash of €25.6 million on September 30, 2022 October 19, 2022 – release at 7:30 am CET

Sophia Antipolis, France



Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today provided financial and business highlights for the third quarter 2022 for Nicox SA and its subsidiaries (the 'Nicox Group') and confirmed timing for the upcoming NCX 470 Mont Blanc Phase 3 clinical trial milestone.
